Clay Siegall, Seagen CEO (Life Science Washington via YouTube)

UP­DAT­ED: Ar­rest re­port, court docs out­line mul­ti­ple spouse abuse al­le­ga­tions against Seagen founder Clay Sie­gall

New in­for­ma­tion has emerged de­tail­ing the events that led to the April 23 ar­rest of Seagen CEO Clay Sie­gall and a May 2 tem­po­rary re­strain­ing or­der against him, ac­cord­ing to doc­u­ments ob­tained by End­points News.

Around 3 a.m. lo­cal time on April 23, Sie­gall’s wife and a wit­ness called po­lice af­ter he al­leged­ly pushed her to the ground, and he was brought to jail hours lat­er on a charge of fourth de­gree do­mes­tic vi­o­lence gross mis­de­meanor, per po­lice records from that morn­ing. The records, as well as a re­strain­ing or­der and jail call logs, lay out the al­le­ga­tions against one of the high­est-pro­file CEOs in biotech, who found­ed Seagen in the late 1990s and has built it in­to a $22 bil­lion drug de­vel­op­er that led the ADC R&D field. Sie­gall was al­so one of the most rich­ly com­pen­sat­ed phar­ma ex­ec­u­tives in 2021, pulling in $18.1 mil­lion.

Sie­gall’s lawyer did not im­me­di­ate­ly re­spond to an email and phone call re­quests for com­ment. This sto­ry will be up­dat­ed ac­cord­ing­ly.

The de­tails come to light af­ter Seagen said Mon­day that Clay Sie­gall was placed on leave for do­mes­tic vi­o­lence al­le­ga­tions, which the com­pa­ny said he de­nied. Seagen’s board al­so launched its own in­ves­ti­ga­tion in­to the mat­ter.

Umo­ja Bio­phar­ma, a pri­vate­ly held biotech that Sie­gall chaired, said Wednes­day af­ter mar­ket close that he agreed to the start­up’s re­quest to re­sign from the board, ef­fec­tive im­me­di­ate­ly. Pub­licly trad­ed Nurix Ther­a­peu­tics, an­oth­er biotech that Sie­gall is on the board of, told End­points in an emailed state­ment: “Sie­gall’s sta­tus at Nurix is un­changed. We con­tin­ue to mon­i­tor the sit­u­a­tion, and we will be guid­ed by our com­mit­ment to the high­est eth­i­cal stan­dards as sum­ma­rized by Nurix’s Code of Busi­ness Con­duct & Ethics.”

“Seagen has high stan­dards for em­ploy­ee con­duct and con­demns do­mes­tic vi­o­lence in all its forms. We are treat­ing these al­le­ga­tions with the ut­most se­ri­ous­ness. Dr. Sie­gall re­mains on a leave of ab­sence while the com­pa­ny’s Board of Di­rec­tors, led by a com­mit­tee of in­de­pen­dent di­rec­tors, con­ducts a thor­ough in­ves­ti­ga­tion with the as­sis­tance of an in­de­pen­dent law firm. The Board’s fu­ture de­ci­sions will be in­formed by the out­come of the in­ves­ti­ga­tion,” a com­pa­ny spokesper­son said in an emailed state­ment to End­points on Wednes­day.

In a 58-page po­lice doc­u­ment de­tail­ing the April 23 ar­rest at the cou­ple’s home in the Seat­tle area, Clay Sie­gall and his wife were out to din­ner with six oth­ers be­fore they all re­turned to the cou­ple’s home. Four of the oth­ers left be­fore the al­leged in­ci­dent oc­curred.

Per a wit­ness ac­count in­clud­ed in the po­lice re­port, Clay Sie­gall pushed his wife to the ground, and grabbed and pulled her by her arms. Sie­gall then went to bed and the in­di­vid­ual called the po­lice on their dri­ve home. Sie­gall’s wife al­so called the po­lice, the re­port said.

Dur­ing his wife’s call with the po­lice dis­patch­er, she said to “erase the phone call” and that she “did not mean to call.” She asked for the po­lice not to come.

“Please don’t send any­one, I messed up by call­ing, he’ll kill me if he know I called … I ac­ci­den­tal­ly picked up the phone and pressed 9-1-1 and shouldn’t have,” she said, ac­cord­ing to the re­port.

“He pushed me on the floor, he video­taped every­thing,” she added.

She de­clined to give po­lice the code to the house’s front gate, but the gate was al­ready open and the po­lice en­tered. The of­fi­cers knocked on the door and she let them in. Clay Sie­gall came down­stairs and spoke to the po­lice af­ter re­ceiv­ing a phone call from of­fi­cers try­ing to lo­cate him. Cit­ing the size of the house, the of­fi­cers called sur­round­ing po­lice de­part­ments to as­sist with the search, ac­cord­ing to the records.

Per the re­port, when speak­ing to the of­fi­cers, Sie­gall’s wife men­tioned her hus­band’s pub­lic vis­i­bil­i­ty as a rea­son not to come.

“[She] said her hus­band will kill her. [She] then added, ‘Please leave and go away,’ ‘He’ll go crazy, he’s a pub­lic fig­ure,’” ac­cord­ing to the po­lice records.

Ac­cord­ing to an­oth­er of­fi­cer’s re­port of the in­ci­dent: “I asked her what hap­pened but she did not want to tell me as she said her hus­band would kill her. I asked if she re­al­ly thought he would or she was just us­ing that lan­guage and she would just kept say­ing [sic] I did not un­der­stand and her hus­band was a pub­lic fig­ure.”

Clay Sie­gall de­nied touch­ing his wife, ac­cord­ing to the po­lice re­ports. He was ar­rest­ed and tak­en in­to jail that day. While there, he called his wife mul­ti­ple times and blamed her for his be­ing in jail, and he al­so called a DUI lawyer, ac­cord­ing to the records.

“Clay thanked her for the pos­si­bil­i­ty that he may get fired and that she may have ru­ined his ca­reer,” ac­cord­ing to a sum­ma­ry of the call logs from jail.

Days af­ter the in­ci­dent, his wife went to the po­lice sta­tion and said she had bruis­es from the evening of the ar­rest and want­ed them doc­u­ment­ed. An of­fi­cer took pho­tos of bruis­es on her arms, face, legs and hips, ac­cord­ing to the re­ports.

“She didn’t re­al­ize how bad she was hurt un­til the fol­low­ing morn­ing when she be­gan see­ing the bruis­es,” ac­cord­ing to the re­ports. She dis­cussed hav­ing reg­u­lar “hid­ing” places at their house in an­tic­i­pa­tion of his es­ca­lat­ed moods, and de­scribed Sie­gall as ver­bal­ly abu­sive, ag­gres­sive and con­trol­ling.

Then, on May 2, a lo­cal coun­ty court is­sued a tem­po­rary or­der re­strain­ing Clay Sie­gall from com­ing with­in 100 yards of his wife. The court cit­ed “an emer­gency ex­ists” as rea­son­ing for the or­der, which lasts un­til a hear­ing for the pro­tec­tion or­der pe­ti­tion takes place. The hear­ing is set for next week.

In his wife’s pe­ti­tion, she cites years of var­i­ous forms of abuse from Clay Sie­gall at their homes in Wash­ing­ton and Cal­i­for­nia, as well as on busi­ness and va­ca­tion trips. In one in­stance of the phys­i­cal al­ter­ca­tions, she al­leged Clay Sie­gall pulled out one of her drainage tubes while he drove her home af­ter a surgery. Ad­di­tion­al­ly, the night be­fore their wed­ding, se­cu­ri­ty had to be called be­cause of a loud fight, she wrote in the pe­ti­tion. He held her down or against the wall “at least a dozen times,” she al­leged.

“He treat­ed me like a beau­ti­ful slave. Arm can­dy that looked nice on his arm when we went out and that cooked, cleaned and took care of him and his fam­i­ly when we were home. I lived day to day walk­ing on eggshells,” she wrote in the pe­ti­tion. The cou­ple has al­so gone through ther­a­py, she wrote.

The cou­ple had sep­a­rat­ed in Feb­ru­ary 2021 and ini­ti­at­ed di­vorce pro­ceed­ings in both states. She had been grant­ed a pro­tec­tion or­der in Cal­i­for­nia to pro­tect her from “Clay’s an­gry, vi­o­lent, con­trol­ling and threat­en­ing be­hav­ior” at the time.

Then, in June 2021, the cou­ple moved back in to­geth­er and paused the di­vorce pro­ceed­ings. In De­cem­ber 2021, the cou­ple dropped lit­i­ga­tion against each oth­er, per the May 2 pe­ti­tion.

One in three women and one in four men have ex­pe­ri­enced a form of phys­i­cal vi­o­lence by an in­ti­mate part­ner, ac­cord­ing to the CDC. As­sis­tance and sup­port for vic­tims of do­mes­tic vi­o­lence are avail­able at the na­tion­al hot­line: 1-800-799-7233.

2023 Spot­light on the Fu­ture of Drug De­vel­op­ment for Small and Mid-Sized Biotechs

In the context of today’s global economic environment, there is an increasing need to work smarter, faster and leaner across all facets of the life sciences industry.  This is particularly true for small and mid-sized biotech companies, many of which are facing declining valuations and competing for increasingly limited funding to propel their science forward.  It is important to recognize that within this framework, many of these smaller companies already find themselves resource-challenged to design and manage clinical studies themselves because they don’t have large teams or in-house experts in navigating the various aspects of the drug development journey. This can be particularly challenging for the most complex and difficult to treat diseases where no previous pathway exists and patients are urgently awaiting breakthroughs.

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product approved since last November, leaving many sponsors in limbo on what to expect.

That silence means that for more than 70 orphan-designated indications for more than 60 products, OOPD has issued no public determination on the seven-year orphan exclusivity in the Orange Book, and no new listings of orphan exclusivity appear in OOPD’s searchable database, as highlighted recently by George O’Brien, a partner in Mayer Brown’s Washington, DC office.

Am­gen, years be­hind ri­vals, says PhI obe­si­ty drug shows dura­bil­i­ty signs

While NBC ran “The Biggest Loser” for 17 seasons, deemed toxic by critics for the reality show’s punishing exercise and diet upheavals, researchers in pharmaceutical labs have been attempting to create prescription drugs that induce weight loss — and one pharma betting it can require less frequent dosing is out with a new crop of data.

Amgen was relatively late to the game compared to its approved competitor Novo Nordisk and green light-approaching rival Eli Lilly. But early data suggested Amgen’s AMG 133 led to a 14.5% weight reduction in the first few months of dosing, buoying shares earlier this fall, and now the California pharma is out with its first batch of durability data showing that figure fell slightly to 11.2% about 150 days after the last dose. Amgen presented at the 20th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease on Saturday afternoon.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Big week for Alzheimer’s da­ta; As­traZeneca buys cell ther­a­py start­up; Dig­i­tal ther­a­peu­tics hits a pay­er wall; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

You may start to notice more stories exclusively available to Premium subscribers. This week alone, paid subscribers can read our in-depth reporting on Alzheimer’s data, digital therapeutics and Allogene’s cell therapy for solid tumors, as well as scoops on Twitter ads and Catalent. With your support, we can keep growing our team and spend more time on quality work. We have both individual and company plans available — check them out to unlock the full Endpoints experience.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Illustration: Assistant Editor Kathy Wong for Endpoints News

As mon­ey pours in­to dig­i­tal ther­a­peu­tics, in­sur­ance cov­er­age crawls



Talk therapy didn’t help Lily with attention deficit hyperactivity disorder, or ADHD. But a video game did.

As the 10-year-old zooms through icy waters and targets flying creatures on the snow-capped planet Frigidus, she builds attention skills, thanks to Akili Interactive Labs’ video game EndeavorRx. She’s now less anxious and scattered, allowing her to stay on a low dose of ADHD medication, according to her mom Violet Vu.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Eli Lil­ly’s Alzheimer’s drug clears more amy­loid ear­ly than Aduhelm in first-ever head-to-head. Will it mat­ter?

Ahead of the FDA’s decision on Eli Lilly’s Alzheimer’s drug donanemab in February, the Big Pharma is dropping a first cut of data from one of the more interesting trials — but less important in a regulatory sense — at an Alzheimer’s conference in San Francisco.

In the unblinded 148-person study, Eli Lilly pitted its drug against Aduhelm, Biogen’s drug that won FDA approval but lost Medicare coverage outside of clinical trials. Notably, the study didn’t look at clinical outcomes, but rather the clearance of amyloid, a protein whose buildup is associated with Alzheimer’s disease, in the brain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

US month­ly costs for biosim­i­lars 'sub­stan­tial­ly high­er' than Ger­many or Switzer­land, JA­MA re­search finds

As the global biologics market is expected to hit nearly the half-trillion-dollar mark this year, new JAMA research points to the importance of timely biosimilar entry, particularly as fewer biosimilars are entering the US than in Europe, and as monthly treatment costs for biosimilars were “substantially higher” in the US compared with Germany and Switzerland.

Among the three countries, biosimilar market share at launch was highest in Germany, but increased at the fastest rate in the US, the authors from the University of Zurich’s Institute of Law wrote in JAMA Network Open today.

Kirk Myers is shown in a still image from a new film series showcasing the efforts of HIV advocates funded by Gilead.

Gilead spot­lights HIV projects and the com­mu­ni­ty lead­ers dri­ving them in new mi­ni-doc­u­men­tary films

Gilead is going behind the scenes of some of the HIV initiatives it funds through grants in a new film series narrated by the people helming the projects.

The first four films and leaders come from across the US — Arianna Lint in Florida and Puerto Rico, Cleve Jones in San Francisco, June Gipson in Mississippi and Kirk Myers in Texas. Their HIV-focused efforts range from addressing unmet needs of the transgender community to delivering social services and high-quality health care in underserved communities.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

EMA pulls an opi­oid from the 1950s used to treat dry cough

The European Medicines Agency said Friday that it’s pulling from all European markets pholcodine-containing medicines, which are an opioid used in adults and children for the treatment of dry cough and in combo with other drugs as a treatment for cold and flu.

The decision to pull the medicines comes as the EMA points to the results from the recent ALPHO study, which show that use of pholcodine during the 12 months preceding anesthesia is linked to a risk of an anaphylactic reaction related to the neuromuscular blocking agents (NMBAs) used (with an adjusted OR of 4.2, and a 95% confidence interval of 2.5 to 6.9).